ALX ONCOLOGY HOLDINGS INC (ALXO) Form 8-K — Oct 15, 2026
$ALXOForm 8-KItems 1.01, 3.02, 9.01Filed Oct 15, 2026, 4:55 PM ET0001193125-26-422992Original filing
ALX Oncology entered into exchange agreements on October 14, 2026 under which stockholders, including funds affiliated with Blackstone Annex Master Fund L.P., RA Capital, and venBio, will surrender 13,353,384 shares of common stock to the Company. In return, the Company will issue pre-funded warrants to purchase the same 13,353,384 shares at an exercise price of $0.001 per share, with the exchange settling on or about October 15, 2026 under the Section 3(a)(9) registration exemption.
Key figures
- Offering Price
- 0.001
- Shares Offered
- 13353384
- Max ownership increase
- 19.99%
- Venbio shares exchanged
- 253826
- Beneficial ownership caps
- ["4.99%","9.99%"]
- Blackstone shares exchanged
- 12885891
- Ra capital shares exchanged
- 213667
- Warrant exercise price per share
- 0.001
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.